I do not like sidekicks like this. Many preclinical studies are done in big indications by ATH, but not published and FA is small and even smaller than MSA as an indication. The company classifies this as "no price sensitive". With this small market capital positive "price-sensitive" news is needed. Most likely Dr. Pall initiated this study and I think ATH could live even without this until it can afford side-kicks in FA.
I do not like sidekicks like this. Many preclinical studies are...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $6.663K | 1.332M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 46 | 38364906 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 20752393 | 17 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.5¢ | 1264516 | ||
| Last updated 14.17pm 17/05/2024 ? | |||||
| ATH (ASX) Chart |